Science Behind Osteomyelitis And Its Prevention Market Outlook: Ken Research

0


According to the study OSTEOMYELITIS GLOBAL CLINICAL TRIALS REVIEW, H1, 2018, this infection is usually treated with antibiotics given into veins or through surgery.

Osteomyelitis is an infection of a bone caused by bacteria, mostly Staphylococcus aureus. It is pretty rare and certain chronic conditions like diabetes tend to increase the risk of osteomyelitis. It results in pain and redness around the affected region apart from symptoms like fever, nausea and chills. The disease can easily be diagnosed by X-ray, CT scan and blood tests. There are currently many advances being made in surgical treatment and medicine which are incorporating technology and research. The result of these advances in surgical treatment and antibiotic therapy is opening doors for various treatment options of osteomyelitis. The barriers to proper treatment are being studied in order to better understand the ways to intrude them. This can be proven by the developments that have taken place in osteomyelitis treatment such as the study carried out by research teams. An Institut Pasteur-CNRS research team has characterized a Staphylococcus aureus gene involved in virulence, bio film formation and resistance to certain antibiotics.

Since osteomyelitis is mainly an infection, it can easily flourish around open wounds and recently treated areas around bones. New technologies for the prevention of healthcare associated infections are increasingly being developed and marketed to healthcare centers worldwide. This comes due to the realization of the fact that while there is substantial promise in simulated test environments, decreasing infections in the clinical setting has not been well established. There are a number of factors that raise concern in this respect, the most common ones being cross transmission in the hospital environment arising from contamination of hospital surfaces, contamination of medical devices and hands or clothes of medical personnel. Studies too show the alarming situation as more than one-third of hospital acquired infections are caused by contamination of medical workers’ hands. A patient admitted to a hospital room in which the previous occupant had methicillin-resistant Staphylococcus aureus has a significantly increased risk of acquiring the pathogens.

In response to the crippling situation, there have been a number of developments like the use of Adenosine triphosphate (ATP) levels and fluorescent markers to monitor the microbial contamination levels. Manual cleaning remains an important precursor step as gross organic soil must be removed from surfaces to allow penetration of germicidal vapour/aerosol or radiation emitted from hydrogen peroxide or UV light emitting devices. Several antimicrobial coatings are under pre-clinical study for their potential application to surfaces in healthcare centers. However, Coatings copper has been studied most extensively.

Antibiotics are increasingly undergoing research to increase their effectiveness. Many pharmaceutical companies are incorporating existing knowledge and expertise in their experiments in an order to expand their scope. Osteomyelitis among other ailments is providing opportunities to the pharmaceutical research sector to tackle microbial attacks. There is growing awareness about prevention of accelerating factors like hygiene and technologies like hand hygiene monitoring systems and antimicrobial textiles among others are said to help change the scenario.

To know more, click on the link below:

https://www.kenresearch.com/healthcare/pharmaceuticals/osteomyelitis-global-clinical-trials-h1-2018/149598-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

+91-9015378249

Share.